S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
The Elites Are Waging War on Elon Musk — Here's Why… (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
Buy THIS stock before Taiwan is attacked (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
The Elites Are Waging War on Elon Musk — Here's Why… (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
Buy THIS stock before Taiwan is attacked (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
The Elites Are Waging War on Elon Musk — Here's Why… (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
Buy THIS stock before Taiwan is attacked (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
The Elites Are Waging War on Elon Musk — Here's Why… (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
Buy THIS stock before Taiwan is attacked (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double

Regulus Therapeutics (RGLS) News Today

$1.54
+0.01 (+0.65%)
(As of 02/20/2024 ET)
SourceHeadline
MarketBeat logoRegulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.com
americanbankingnews.com - February 20 at 2:28 AM
money.usnews.com logoRegulus Therapeutics Inc
money.usnews.com - February 16 at 5:33 PM
MarketBeat logoRegulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Down 7.3% in January
americanbankingnews.com - February 16 at 5:36 AM
MarketBeat logoRegulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com
americanbankingnews.com - February 14 at 3:22 AM
msn.com logoRegulus concludes enrolment in Phase I trial’s third cohort for ADPKD
msn.com - January 3 at 2:56 PM
finance.yahoo.com logoRegulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - January 2 at 5:49 PM
seekingalpha.com logoRegulus Therapeutics files for $150M mixed shelf
seekingalpha.com - December 27 at 5:14 PM
morningstar.com logoRegulus Therapeutics Inc RGLS
morningstar.com - December 23 at 12:14 AM
finance.yahoo.com logoRegulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
finance.yahoo.com - November 22 at 12:57 PM
markets.businessinsider.com logoRegulus Stock Maintains Buy Rating Amid Financial Stability and Positive Clinical Trial Progress
markets.businessinsider.com - November 11 at 9:41 AM
finance.yahoo.com logoRegulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
finance.yahoo.com - November 9 at 7:31 PM
finance.yahoo.com logoRegulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - November 2 at 12:25 PM
finance.yahoo.com logoRegulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - October 19 at 1:24 PM
nasdaq.com logoRegulus Therapeutics (RGLS) Price Target Increased by 13.64% to 6.38
nasdaq.com - October 5 at 8:41 AM
msn.com logoCanaccord Genuity Maintains Regulus Therapeutics (RGLS) Buy Recommendation
msn.com - September 22 at 2:13 PM
markets.businessinsider.com logoAnalyst Expectations for Regulus Therapeutics's Future
markets.businessinsider.com - September 21 at 2:01 PM
msn.com logoRegulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney Disease
msn.com - September 20 at 3:55 PM
markets.businessinsider.com logoRegulus Reports Positive Topline Data From First Cohort Of Patients In Phase 1b Study Of RGLS8429
markets.businessinsider.com - September 20 at 9:41 AM
finance.yahoo.com logoRegulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - September 20 at 9:41 AM
finance.yahoo.com logoRegulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - September 13 at 9:46 AM
finance.yahoo.com logoRegulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
finance.yahoo.com - September 5 at 5:04 PM
gurufocus.com logoRegulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?
gurufocus.com - August 24 at 9:01 PM
finance.yahoo.com logoRegulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
finance.yahoo.com - August 23 at 5:38 PM
finance.yahoo.com logoRegulus Therapeutics to Host Virtual Investor Event on September 6, 2023
finance.yahoo.com - August 23 at 8:35 AM
markets.businessinsider.com logoRegulus (RGLS) Gets a Buy from H.C. Wainwright
markets.businessinsider.com - August 9 at 3:48 PM
finance.yahoo.com logoRegulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
finance.yahoo.com - August 8 at 9:15 PM
finance.yahoo.com logoRegulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
finance.yahoo.com - August 2 at 12:38 PM
finance.yahoo.com logoRegulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
finance.yahoo.com - July 18 at 1:04 PM
markets.businessinsider.com logoExpert Ratings for Regulus Therapeutics
markets.businessinsider.com - June 28 at 1:59 PM
markets.businessinsider.com logoH.C. Wainwright Remains a Buy on Regulus (RGLS)
markets.businessinsider.com - June 28 at 8:59 AM
finance.yahoo.com logoRegulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - June 27 at 9:01 AM
finance.yahoo.com logoRegulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
finance.yahoo.com - June 23 at 8:37 AM
finance.yahoo.com logoRegulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
finance.yahoo.com - June 20 at 9:44 AM
fool.com logoRegulus Therapeutics (NASDAQ: RGLS)
fool.com - June 16 at 2:15 PM
finance.yahoo.com logoRegulus Therapeutics Strengthens Research & Development Leadership
finance.yahoo.com - June 12 at 6:50 PM
finance.yahoo.com logoRegulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - May 16 at 8:37 AM
msn.com logoHC Wainwright & Co. Reiterates Regulus Therapeutics (RGLS) Buy Recommendation
msn.com - May 15 at 8:42 PM
finanznachrichten.de logoRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
finanznachrichten.de - May 12 at 8:36 AM
seekingalpha.com logoRegulus Therapeutics GAAP EPS of -$0.42 beats by $0.02
seekingalpha.com - May 11 at 8:47 PM
finance.yahoo.com logoRegulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
finance.yahoo.com - May 11 at 8:47 PM
msn.com logoHC Wainwright & Co. Maintains Regulus Therapeutics (RGLS) Buy Recommendation
msn.com - April 21 at 12:44 PM
msn.com logoWhy Regulus Therapeutics Shares Are Trading Higher Today
msn.com - April 13 at 12:45 PM
finance.yahoo.com logoRegulus Therapeutics Announces $15 Million Private Placement of Equity
finance.yahoo.com - April 13 at 12:45 PM
finance.yahoo.com logoRegulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - April 12 at 9:01 PM
benzinga.com logoRegulus Therapeutics Stock (NASDAQ:RGLS), Short Interest Report
benzinga.com - March 25 at 4:52 AM
finanznachrichten.de logoRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates
finanznachrichten.de - March 24 at 7:27 AM
finance.yahoo.com logoRegulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates
finance.yahoo.com - March 23 at 8:59 PM
benzinga.com logoRegulus Therapeutics Stock (NASDAQ:RGLS), Guidance and Forecast
benzinga.com - March 9 at 12:27 AM
finance.yahoo.com logoRegulus Therapeutics to Present at the SVB Securities Global Biopharma Conference
finance.yahoo.com - February 9 at 9:34 AM
forbes.com logoRegulus Therapeutics
forbes.com - January 26 at 3:20 PM
Get Regulus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.



RGLS Media Mentions By Week

RGLS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RGLS
News Sentiment

0.25

0.54

Average
Medical
News Sentiment

RGLS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RGLS Articles
This Week

4

0

RGLS Articles
Average Week

Get Regulus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:RGLS) was last updated on 2/21/2024 by MarketBeat.com Staff